Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Zai Lab Limited - American Depositary Shares
(NQ:
ZLAB
)
36.82
-0.98 (-2.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Zai Lab Limited - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Netflix, BlackSky Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
July 18, 2025
Via
Benzinga
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
July 10, 2025
From
Zai Lab Limited
Via
Business Wire
Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects
June 30, 2025
Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected later.
Via
Benzinga
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
June 30, 2025
From
Zai Lab Limited
Via
Business Wire
Earnings Scheduled For May 8, 2025
May 08, 2025
Via
Benzinga
ZAI LAB LTD-ADR (NASDAQ:ZLAB) – A High-Growth Biotech Stock Meeting Minervini’s Criteria
June 16, 2025
ZAI LAB LTD-ADR (NASDAQ:ZLAB) is a high-growth biotech stock meeting Minervini’s Trend Template with strong revenue growth, technical strength, and sector leadership.
Via
Chartmill
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
June 13, 2025
From
Zai Lab Limited
Via
Business Wire
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
June 08, 2025
Via
Benzinga
Guidewire Software Posts Upbeat Q3 Results, Joins Yext, REV Group And Other Big Stocks Moving Higher On Wednesday
June 04, 2025
Via
Benzinga
Wednesday's session: gap up and gap down stocks
June 04, 2025
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
June 02, 2025
TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial.
Via
Benzinga
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
June 02, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
May 31, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in Investor Conferences in June 2025
May 30, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
May 19, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
May 08, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
April 25, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
April 23, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
April 21, 2025
From
Zai Lab Limited
Via
Business Wire
Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Others In Your Portfolio?
April 20, 2025
Top mid-cap performers last week: Webull Corp, Hertz Global, Metsera Inc, Vista Energy, Certara Inc, Sibanye-Stillwater, Banco Macro, Grupo Financiero Galicia, Banco BBVA Argentina, Recursion...
Via
Benzinga
Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025
April 14, 2025
From
Zai Lab Limited
Via
Business Wire
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
April 11, 2025
Via
Benzinga
Why ZAI LAB LTD-ADR (NASDAQ:ZLAB) could fit Mark Minervini’s high-growth criteria
April 03, 2025
A fundamental and technical analysis of (NASDAQ:ZLAB): Why the high growth investor may take a look at ZAI LAB LTD-ADR (NASDAQ:ZLAB).
Via
Chartmill
No Fear And No Panic After A 10% Correction = No Bottom
March 28, 2025
In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off.
Via
Talk Markets
Topics
Stocks / Equities
Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday
March 28, 2025
Via
Benzinga
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday
March 27, 2025
Via
Benzinga
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
March 26, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
March 12, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in Investor Conferences in March 2025
March 03, 2025
From
Zai Lab Limited
Via
Business Wire
NovoCure Q4 EPS Misses, Revenue Matches
February 27, 2025
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.